1 min read
Add as a preferred source on Google

Emmaus Life Sciences Reports $0.07 Q3 Loss as Revenue Falls 43.8%

Third-quarter revenue was $1.9 million. Cash and cash equivalents totaled $1.0 million at Sept. 30, down from $2.1 million at Dec. 31, 2025.

A nearly empty cash box beside a small pharmaceutical vial / TokenPost.ai
A nearly empty cash box beside a small pharmaceutical vial / TokenPost.ai

Emmaus Life Sciences posted a third-quarter GAAP loss of $0.07 per share as revenue fell 43.8% year over year to $1.9 million.

The company had $1.0 million in cash and cash equivalents at Sept. 30, compared with $2.1 million at Dec. 31, 2025.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…